STOCK TITAN

Recursion (NASDAQ: RXRX) CSO RSU tax withholding on 26,657 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Recursion Pharmaceuticals Chief Scientific Officer David Hallett reported a tax-related share disposition. On this Form 4, 26,657 shares of Class A Common Stock were withheld at a price of $3.04 per share to cover tax obligations tied to restricted stock units.

These shares were retained by the company to satisfy withholding and remittance duties in connection with net-settled RSUs, not sold on the open market. After this withholding event, Hallett directly holds 1,070,494 shares of Class A Common Stock.

Positive

  • None.

Negative

  • None.

Insights

Routine tax withholding; no open-market trading signal.

The transaction is coded "F" and described as tax-withholding, with 26,657 shares withheld at $3.04 per share to settle obligations from restricted stock units. This is a mechanical step linked to equity compensation rather than a discretionary trade.

Following the event, David Hallett holds 1,070,494 shares of Class A Common Stock, indicating a substantial continuing stake. Because no open-market buying or selling occurred, the informational value for sentiment is limited, and the filing appears administratively routine.

Insider Hallett David
Role Chief Scientific Officer
Type Security Shares Price Value
Tax Withholding Class A Common Stock 26,657 $3.04 $81K
Holdings After Transaction: Class A Common Stock — 1,070,494 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares withheld for taxes 26,657 shares Tax-withholding disposition from RSU net settlement
Withholding price per share $3.04 per share Valuation used for RSU-related tax withholding
Shares held after transaction 1,070,494 shares Class A Common Stock directly held by David Hallett after event
Form 4 regulatory
"Please analyze the following financial content according to the instructions above. INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Class A Common Stock financial
""security_title": "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
restricted stock units financial
"in connection with the net settlement of restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding financial
"to satisfy its tax withholding and remittance obligations"
Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.
net settlement financial
"in connection with the net settlement of restricted stock units."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hallett David

(Last)(First)(Middle)
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET

(Street)
SALT LAKE CITY UTAH 84101

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock05/15/2026F(1)26,657D$3.041,070,494D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
Remarks:
/s/Jonathan Golightly, attorney-in-fact05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Recursion Pharmaceuticals (RXRX) report for David Hallett?

Recursion Pharmaceuticals reported a Form 4 for David Hallett showing 26,657 Class A shares withheld at $3.04 per share for tax obligations linked to restricted stock units, rather than an open-market stock sale or purchase.

Was the RXRX Form 4 for David Hallett an open-market sale of shares?

No, the Form 4 shows a tax-withholding disposition coded "F," where 26,657 shares were withheld by the issuer to satisfy tax and remittance obligations from net settlement of restricted stock units, not a voluntary market sale.

How many RXRX shares does David Hallett hold after this Form 4 transaction?

After the tax-withholding disposition, David Hallett directly holds 1,070,494 shares of Recursion Pharmaceuticals Class A Common Stock, according to the Form 4, indicating a large continuing ownership position after the compensation-related adjustment.

What does transaction code "F" mean in the Recursion Pharmaceuticals (RXRX) Form 4?

Transaction code "F" indicates payment of exercise price or tax liability by delivering securities. Here it reflects shares withheld by Recursion Pharmaceuticals to cover tax obligations associated with the net settlement of restricted stock units granted to David Hallett.

What price per share was used for the RXRX tax-withholding disposition?

The Form 4 reports a transaction price of $3.04 per share for the 26,657 Recursion Pharmaceuticals Class A shares withheld for tax obligations related to restricted stock units, establishing the valuation used for this compensation-linked withholding event.